A single administration resulted in dose-dependent tumor inhibition and prolonged survival without observable toxicity. These findings highlight [225Ac]Ac-Macropa-PEG4-FPA150 as a promising candidate for B7-H4 targeted TAT and support Macropa as an effective chelator for 225Ac radiopharmaceuticals.

22 days ago

Journal

VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)

alsevalimab (FPA150)

over1year

FPA150-001: FPA150 in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=95, Terminated, Five Prime Therapeutics, Inc. | Phase classification: P1a/1b --> P1 | Completed --> Terminated; The Sponsor terminated the study for reasons unrelated to safety.

over 1 year ago

Phase classification • Trial termination • Metastases

VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)

VTCN1 underexpression

Keytruda (pembrolizumab) • alsevalimab (FPA150)

over4years

FPA150-001: FPA150 in Patients With Advanced Solid Tumors (clinicaltrials.gov)

P1a/1b, N=95, Completed, Five Prime Therapeutics, Inc. | Active, not recruiting --> Completed | N=278 --> 95 | Trial completion date: Jan 2022 --> May 2021 | Trial primary completion date: Jan 2022 --> May 2021

over 4 years ago

Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date

VTCN1 (V-Set Domain Containing T Cell Activation Inhibitor 1)

VTCN1 underexpression

Keytruda (pembrolizumab) • alsevalimab (FPA150)